MX2021010398A - Metodo para tratar un mieloma multiple. - Google Patents

Metodo para tratar un mieloma multiple.

Info

Publication number
MX2021010398A
MX2021010398A MX2021010398A MX2021010398A MX2021010398A MX 2021010398 A MX2021010398 A MX 2021010398A MX 2021010398 A MX2021010398 A MX 2021010398A MX 2021010398 A MX2021010398 A MX 2021010398A MX 2021010398 A MX2021010398 A MX 2021010398A
Authority
MX
Mexico
Prior art keywords
treating
multiple myeloma
subject
administering
effective amount
Prior art date
Application number
MX2021010398A
Other languages
English (en)
Inventor
Marla L Weetall
Liangxian Cao
Arnold Bolomsky
Heinz Ludwig
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of MX2021010398A publication Critical patent/MX2021010398A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un aspecto descrito en la presente solicitud incluye un método para tratar un mieloma múltiple (MM) en un individuo que lo necesite que comprende, administrar al individuo una cantidad efectiva de un compuesto de molécula pequeña. De manera más particular, otro aspecto descrito en la presente solicitud incluye un método para tratar un mieloma múltiple en un individuo que lo necesite que comprende, administrar al individuo una cantidad efectiva del compuesto de molécula pequeña descrito en la presente solicitud en combinación con un agente quimioterapéutico.
MX2021010398A 2019-02-28 2020-02-26 Metodo para tratar un mieloma multiple. MX2021010398A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962812002P 2019-02-28 2019-02-28
PCT/US2020/019884 WO2020176610A1 (en) 2019-02-28 2020-02-26 Method for treating a multiple myeloma

Publications (1)

Publication Number Publication Date
MX2021010398A true MX2021010398A (es) 2022-01-18

Family

ID=72238680

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010398A MX2021010398A (es) 2019-02-28 2020-02-26 Metodo para tratar un mieloma multiple.

Country Status (11)

Country Link
US (1) US20220143016A1 (es)
EP (1) EP3931196A4 (es)
JP (1) JP2022521801A (es)
CN (1) CN113710670A (es)
AU (1) AU2020227748A1 (es)
BR (1) BR112021016747A2 (es)
CA (1) CA3131249A1 (es)
EA (1) EA202192117A1 (es)
IL (1) IL285800A (es)
MX (1) MX2021010398A (es)
WO (1) WO2020176610A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (es) * 1973-09-20 1977-11-30 Delalande Sa
AU2002228922A1 (en) * 2000-12-12 2002-06-24 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
CA2813003A1 (en) * 2010-10-05 2012-04-12 Fresenius Kabi Usa, Llc Bortezomib formulations stabilised with boric acid
PE20151413A1 (es) * 2012-11-21 2015-10-23 Ptc Therapeutics Inc Inhibidores de bmi-1 de pirimidina inversa sustituida
JP2021535198A (ja) * 2018-08-17 2021-12-16 ピーティーシー セラピューティクス， インコーポレイテッド 膵臓癌を治療する方法
EP3938368B1 (en) * 2019-03-11 2023-06-07 PTC Therapeutics, Inc. Compound form having enhanced bioavailability and formulations thereof

Also Published As

Publication number Publication date
CN113710670A (zh) 2021-11-26
EP3931196A4 (en) 2022-12-14
US20220143016A1 (en) 2022-05-12
CA3131249A1 (en) 2020-09-03
AU2020227748A1 (en) 2021-09-16
IL285800A (en) 2021-10-31
EP3931196A1 (en) 2022-01-05
EA202192117A1 (ru) 2021-11-23
JP2022521801A (ja) 2022-04-12
WO2020176610A1 (en) 2020-09-03
WO2020176610A8 (en) 2021-08-12
BR112021016747A2 (pt) 2021-10-19

Similar Documents

Publication Publication Date Title
MX2023005160A (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma.
MX2022014548A (es) Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1).
IL288236A (en) 3,2-dihydroquinazoline compounds as inhibitors of nav1.8
MX2022007968A (es) Dosificacion de gamma-hidroxibutirato (ghb).
MD20130089A2 (ro) Metodă de tratament al mielomului multiplu
CL2020003276A1 (es) Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
MY197758A (en) Methods for treating conditions associated with masp-2 dependent complement activation
MX2022001004A (es) Inhibidores de enzimas.
MY198004A (en) Antitumoral compounds
PH12019501722A1 (en) Compositions and methods for promoting hair growth with mpc1 inhibitors
MX2019010101A (es) Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc1.
BR112019003130A2 (pt) agonista de ppargama para tratamento de cânceres de sangue
ZA202207328B (en) Zeolite composition suitable for tanning leather
MX2021014309A (es) Composicion para alimentos de animales que contiene los compuestos del componente hexahidro-?-acido y aplicacion de la misma.
ZA202106519B (en) Caspase inhibitors and methods of use thereof
MX2020013510A (es) Composiciones para tratamiento, y metodos para fabricar y usar las mismas.
IL288864A (en) Treatment that includes sglt inhibitors, for example sglt 1/2 inhibitors
CL2021001922A1 (es) Procedimientos para tratamiento de enfermedades con inhibidores de magl.
MX2017012759A (es) Moléculas pequeñas que contienen boro como agentes antiprotozoarios.
MX2016002308A (es) Tratamiento del mieloma multiple.
MX2021010398A (es) Metodo para tratar un mieloma multiple.
MX2020008689A (es) Composicion herbicida que comprende por lo menos un compuesto activo fenolico.
MX2021011688A (es) Combinaciones utiles en un metodo para tratar sarcoma.
MX2019008535A (es) Agonista del ppar gamma para el tratamiento de la enfermedad de huntington.
MX2021008523A (es) Metodo para tratar una leucemia mieloide aguda.